-
ACLA Submits Comments on CMS’ CRUSH RFI
-
ACLA Responds to HHS RFI on AI in Clinical Care
-
ACLA Written Testimony: Legislative Proposals to Support Patient Access to Medicare Services
-
Letter from Leading Patient and Consumer Groups on Passing the RESULTS Act
-
Letter from Leading Provider Groups on Passing the RESULTS Act
-
ACLA Comments on MoldDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer dLCD
-
ACLA Comments on the Draft Local Coverage Determination MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis (DL40187)
-
ACLA Response to CMS-R-131 ABN Updates
-
ACLA Responds to OMB RFI on Deregulation
-
Medical Laboratory Professionals Week (MLPW) Toolkit
